Shopping Cart 0
Cart Subtotal
USD 0

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

KOL Perspectives: IL-6 inhibitors in Rheumatoid Arthritis

Summary

This KOL Insight briefing focuses on perceptions of IL-6 inhibitors in rheumatoid arthritis (RA).

The briefing includes analysis of KOL opinion on the following topic areas-

- Current or anticipated future use of sarilumab in RA

- Current use of tocilizumab in RA

- Expected future change to sarilumab & tocilizumab use

- Comparison of sarilumab & tocilizumab clinical profile in RA

- Non-clinical differentiating factors between sarilumab & tocilizumab

- Impact of and factors contributing to sirukumab discontinuation in RA

- IL-6 inhibitors vs. JAK inhibitors in RA

- KOL awareness of olokizumab currently in development for RA

Key Highlights

- Majority of US but not EU patients have access to sarilumab, with KOLs primarily positioning sarilumab in MTX-IR patients or after anti-TNFs

- Most KOLs position tocilizumab after anti-TNFs, partly due to payer pressure, with first-line use possible in MTX-IR or ineligible patients

- In the next 12 months, most KOLs expect an increase in use of sarilumab, and a reduction in use of tocilizumab.

Scope

- The briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based

- Interviews performed in December 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "IL-6 inhibitors in Rheumatoid Arthritis"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Rheumatoid arthritis, IL-6 inhibitors, sarilumab, tocilizumab, anti-TNFs


Companies

Sanofi

Roche

Genentech

UCB

GSK